Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease
Andrew McGarry(Cooper Medical School of Rowan University), Michael R. Hayden(University of British Columbia), Spyridon Papapetropoulos(Teva Pharmaceuticals (United States)), Peggy Auinger(University of Rochester Medical Center), Victor Abler(Kansas City VA Medical Center), Karl Kieburtz(Beth Israel Deaconess Medical Center), Sanjay Gandhi(Teva Pharmaceuticals (United States)), Igor D. Grachev(Teva Pharmaceuticals (United States))
Cited by 18
Related Papers
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976
Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
|Nature Genetics|1996|577